

^a (a) Iodine, triethylamine. (b) 1,5-Diazabicyclo[4.3.0]non-5-ene. (c) 100 °C, 30 days. (d) Diimide. (e) *tert*-Butyllithium, dimethyl ether, -78 °C. (f) Ozone.

°C gave cyclohexane-1,4-dione and succinic acid. No dione **15** was found. Diene **4** is thermally labile and very sensitive to oxygen and has not yet been isolated in a pure state. Attempts to purify **4** by gas chromatography caused isomerization to **14**: ¹H NMR δ 4.78 (4 H, br s), 3.06 (2 H, br s), 2.45-1.96 (8 H, complex). Ozonolysis of **14** gave dione **15**. The double bonds of **4** are held rigidly parallel and face to face facilitating the Cope rearrangement.

Partial purification of diene **4** after generation from **13** at -78 °C was accomplished by distillation at -25 °C. The vinyl protons of **4** resonate at δ 5.4 in the ¹H NMR spectrum. A Raman spectrum of a mixture of **4** and **14** shows bands at 1620 and 1637 cm⁻¹, which are assigned to the double-bond stretching frequencies of **4** and **14**, respectively. Warming the sample caused the band at 1620 cm⁻¹ to decrease, while the band at 1637 cm⁻¹ increased.

The rate of rearrangement of **4** into **14** has been measured by ¹H NMR spectroscopy by integrating the resonances for the vinyl hydrogens of **4** and **14** using benzene as an internal standard. The reaction rates are shown in Table I. The decrease in the resonance at δ 5.4 is accompanied by twofold increase in the resonance at δ 4.78 and, within the limits of the NMR method, the isomerization of **4** into **14** is quantitative.

In the deiodination of **13**, cleavage of either of the two ethano bridges of the bicyclo[2.2.2]octane ring system would lead directly to **14**. The exclusive formation of **4** by cleavage of the

Table I. Reaction Rates for Isomerization of **4** into **14**

| temp. °C | reaction rate, min ⁻¹ | t _{1/2} , min |
|----------|----------------------------------|------------------------|
| 25 | 2.2 × 10 ⁻³ | 314 |
| 40 | 1.1 × 10 ⁻² | 64 |

E_a = 19.6 kcal/mol

cyclobutano bridge of **13** is a remarkable example of kinetic product control in a reaction.

Acknowledgment is made to the donors of the Petroleum Research Fund, administered by the American Chemical Society, for partial support of this work, and to Badische Anilin Soda Fabrik AG for a gift of cyclooctatetraene used in the preparation of cyclobutene. J.J.V. thanks the University of Michigan for fellowships from the Frank Knoller and A. B. Prescott funds.

References and Notes

- (1) J. Bredt, *Justus Liebigs Ann. Chem.*, **437**, 1 (1924).
- (2) For reviews see (a) G. L. Buchanan, *Chem. Soc. Rev.*, **3**, 41 (1974); (b) G. Kobrich, *Angew. Chem., Int. Ed. Engl.*, **12**, 464 (1973); (c) J. Liebman and A. Greenberg, *Chem. Rev.*, **76**, 311 (1976).
- (3) J. R. Wiseman and W. A. Pletcher, *J. Am. Chem. Soc.*, **92**, 956 (1970).
- (4) Anita O. Sy, Ph.D. Dissertation, University of Michigan, 1977.
- (5) R. L. Viavattene, F. D. Greene, L. D. Cheung, R. Majeste, and L. M. Trefonas, *J. Am. Chem. Soc.*, **96**, 4342 (1974).
- (6) (a) F. Vögtle and P. Neumann, *Top. Curr. Chem.*, **48**, 67 (1974); (b) B. H. Smith, "Bridged Aromatic Compounds", Academic Press, New York, 1964; (c) D. J. Cram and J. M. Cram, *Acc. Chem. Res.*, **4**, 204 (1971).
- (7) (a) S. Masamune, D. W. Brooks, K. Morio, and R. L. Sobczak, *J. Am. Chem. Soc.*, **98**, 8277 (1976); (b) L. T. Scott and W. R. Brunsvold, *ibid.*, **100**, 4320 (1978).
- (8) E. Vogel and H. D. Roth, *Angew. Chem., Int. Ed. Engl.*, **3**, 228 (1964).
- (9) (a) G. M. Whitesides, G. L. Goe, and A. C. Cope, *J. Am. Chem. Soc.*, **91**, 2608 (1969); (b) N. L. Allinger and J. T. Sprague, *ibid.*, **94**, 5734 (1972).
- (10) N. A. Dornin and N. S. Glebovskaya, *J. Gen. Chem. USSR (Engl. Trans.)*, **27**, 723 (1957).
- (11) D. H. R. Barton, R. E. O'Brien, and S. Sternhell, *J. Chem. Soc.*, 470 (1962).
- (12) All new compounds described had infrared, NMR, and mass spectra in accord with assigned structures, and, except for compounds **4** and **10**, elemental analyses within 0.3% of calculated values were obtained.

John R. Wiseman,* Jeffrey J. Vanderbilt

Department of Chemistry, University of Michigan
Ann Arbor, Michigan 48109
Received June 13, 1978

Isolation and Structure of Amoorastatin¹

Sir:


An aqueous extract of *Aphanamixis grandifolia* Bl. seeds was found during an initial study to contain the novel cell growth (murine P388 lymphocytic leukemia) inhibitory tetranortriterpene aphanastatin (**1**).² Further investigation (directed by bioassay) of the same extract, from this interesting Eastern Himalayan (India) plant, for antineoplastic constituents has now led to discovery of a new limonoid³ designated amoorastatin⁴ (**2a**) with even greater cell growth (P388)⁵ inhibitory (ED₅₀ = <0.001 μg/mL) properties. We report that interpretation of spectral data and confirmation by single-crystal X-ray analysis has made possible an unequivocal assignment of structure **2a** (C-28 *R* and *S*) to amoorastatin: mp 205 °C (sintering from 170 °C, crystals from chloroform-methanol); CD in dioxane, Δ_c -4.01 (300 nm) and -3.64 (310 nm).

High resolution mass spectrometry allowed assignment of molecular formula C₂₈H₃₆O₉ (M⁺, *m/e* 516.2362) and significant fragmentation ions were observed at *m/e* 498.2215 (M⁺ - 18), 456.2175 (M⁺ - 60), 438.2057 (M⁺ - 60, - 18) and a diagnostic fragment at 163.0754 (C₁₀H₁₁O₂). Acetylation (acetic anhydride-pyridine) of amoorastatin (**2a**) led to a peracetate derivative (**2b**) corresponding to empirical formula C₃₄H₄₂O₁₂ (M⁺, *m/e* 642): mp 225-228 °C; [α]_D²⁵ -97.4° (c 0.99, chloroform). Comparison of the 250-MHz ¹H NMR spectra obtained from aphanastatin (**1**)² with those of amoorastatin (**2a**) and the peracetate derivative **2b** (Table I) revealed a substantial amount of structural information. By this means it was ascertained that the aphanastatin A-ring substitution pattern was modified and the hydroxyl group at


Table I. Proton Magnetic Resonance Spectra^a of Amoorastatin (**2a**) and the Corresponding Peracetate (**2b**)

| proton position | amoorastatin (2a) ^b | peracetate (2b) ^c |
|-----------------|---|---------------------------------------|
| H-1 | 4.19 (d, $J = 3.3$) | 5.11 (d, $J = 3.0$) |
| H-2 | 2.96 (t, $J = 3.4$) | 2.76 (m) |
| | 3.02 (t, $J = 3.3$) | 2.60 (m) |
| H-3 | 5.55 (d, $J = 3.4$) | 5.32 (d, $J = 2.5$) |
| H-7 | 3.72 (s) | 4.82 (br s) |
| H-9 | 4.72 (s) | 4.08 (s) |
| H-12 | 2.46 (s, 2 H) | 2.39 (AB q, $J = 18$) |
| | | 2.54 |
| H-15 | 3.72 (s) | 3.58 (s) |
| H-17 | 2.74 (m) | 2.68 (t, $J = 11$) |
| H-19 | 4.41 (AB q, $J = 13.3$) | 4.40 (br s, 2 H) |
| | 4.53 | |
| H-21 | 7.11 (s) | 7.11 (s) |
| H-22 | 6.12 (s) | 6.10 (s) |
| H-23 | 7.36 (s) | 7.24 (s) |
| H-28 | 4.98 (s) | 5.80 (s) |
| Me | 0.90 | 0.83 |
| | 1.10 | 1.12 |
| | 1.35 | 1.16 |
| OAc | 1.95 | 1.96 |
| | | 2.02 |
| | | 2.12 |
| | | 2.16 |

^a At 250 MHz, at 22 °C, with chemical shifts in parts per million and coupling constants in hertz. ^b In deuteriochloroform containing 20% pyridine-*d*₅. ^c In deuteriochloroform.



C-12 was missing. The monoacetylated 1,3-glycol system of the amoorastatin A ring was deduced by double resonance experiments. The chemical shifts for this system (δ_H , Table I, and δ_C , 70.8 (d) and 74.5 (d)) indicate the position of the acetate group to be at C-3.⁶ The downfield shift obtained by acetylation of the C-28 hydroxyl group was characteristic of the hemiacetal unit and the C-15 proton at δ 3.72 clearly in-

**Figure 1.** An ORTEP diagram of amoorastatin.

dicated⁷ a 14,15 epoxide. The latter two assignments were further substantiated by inspecting the ¹³C NMR (C-19 at 64.5 (t), C-28 at 96.2 and 95.9 (t), C-14 at 73.4 (s), and C-15 at 57.9 (d)).⁶ The structure assigned, amoorastatin (**2a**), on the basis of these physical measurements was confirmed by a single-crystal X-ray analysis.

Amoorastatin (**2a** as the 28*R* epimer) crystallized with 1 mol of water (mp 170 °C) in the monoclinic form with space group *P*2₁; $a = 7.780$ (2), $b = 12.818$ (2), $c = 13.003$ (3) Å; $\beta = 91.51$ (3)°. The X-ray diffraction data were collected using a Philips PW 1100 diffractometer employing the ω -2 θ scan technique with graphite monochromated Cu K α radiation. The structural problem was solved using a Patterson search program⁸ with the coordinates from the aphanastatin² ring system. A total of 1848 reflections was observed and a full-matrix least-squares refinement, with anisotropic temperature factors for the nonhydrogen atoms, resulted in an *R* factor of 0.052.

The three-dimensional view of amoorastatin (**2a**) shown in Figure 1 substantiates the substituent and configurational assignments as 1 α -OH, 3 α -OAc, 4 α -CH₃, 5 α -H, 7 α -OH, 8 β -CH₃, 9 α -H, 11-oxo, 13 α -CH₃, 14 β ,15 β -epoxy, 17 α -furan, and the hemiacetal ring incorporating carbon atoms C-19 and C-28. Both rings A and B are in the chair conformation and ring C is in a boat conformation. Ring D has assumed an envelope form with C-17 out of the mean plane passing through the other four atoms by 0.64 Å. The dihedral angles between H-7 and the two C-6 hydrogen atoms are -60 and +60°. Between H-15 and the two hydrogen atoms bonded to C-16 the dihedral angles are 48.6 and -73.5°.

Discovery of the structurally simpler amoorastatin (**2a**) with more pronounced cell growth inhibitory activity than aphanastatin (**1**) suggests that the 1 α -acetoxy-, 2 α - and 12 α -dihydroxy-, and 28- α -methylbutyryl groups of aphanastatin are unnecessary and indeed may lessen inhibition of neoplastic (P388) cell growth.

Acknowledgments. We are pleased to thank M. C. Merienne (Laboratoire de RMN à Haut Champs, Orsay) for ¹H NMR measurements at 250 MHz, M. C. Marazano for high resolution mass measurements, Mme. C. Fontaine for the ¹³C NMR spectra, and Linda M. Lange for assistance with biological experiments. The ASU CRI group gratefully acknowledges support of this investigation by Public Health Services Research Grant No. 16049-05 from the National Cancer Institute, the Fannie E. Rippel Foundation, Mrs. Mary Dell Pritzlaff, the Spencer T. and Ann W. Olin Foundation, Mr. John F. Schmidt, and the Phoenix Coca Cola Bottling Co.

References and Notes

- (1) Antineoplastic Agents. 61. For part 60, refer to G. R. Pettit, M. T. Edgar, and T. S. Krupa, *J. Org. Chem.*, in press.
- (2) J. Polonsky, Z. Varon, B. Arnoux, C. Pascard, G. R. Pettit, J. H. Schmltdt, and

